Cellular Immunotherapy for High-grade Glioma

Overview

Journal Immunotherapy

Specialties Allergy & Immunology
Pharmacology

Date 2011 Mar 15

PMID 21395383

Citations 14

Authors

K H Chow

Stephen Gottschalk

Affiliations

Soon will be listed here.

Abstract

The outcome for patients with the most common primary brain tumor, glioblastoma multiforme (GBM), remains poor. Several immunotherapeutic approaches are actively being pursued including antibodies and cell-based therapies. While the blood-brain barrier protects brain tumor cells from therapeutic antibodies, immune cells have the ability to traverse the blood-brain barrier and migrate into GBM tumors to exert their therapeutic function. Results of Phase I clinical studies with vaccines to induce GBM-specific T cells are encouraging and Phase II clinical trials are in progress. Nonvaccine-based cell therapy for GBM has been actively explored over the last four decades. Here we will review past clinical experience with adoptive cell therapies for GBM and summarize current strategies on how to improve these approaches.

Citing Articles

Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.

An Z, Aksoy O, Zheng T, Fan Q, Weiss W Oncogene. 2018; 37(12):1561-1575.

PMID: 29321659 PMC: 5860944. DOI: 10.1038/s41388-017-0045-7.

Integrating the glioblastoma microenvironment into engineered experimental models.

Xiao W, Sohrabi A, Seidlits S Future Sci OA. 2017; 3(3):FSO189.

PMID: 28883992 PMC: 5583655. DOI: 10.4155/fsoa-2016-0094.

Insights into molecular therapy of glioma: current challenges and next generation blueprint.

Rajesh Y, Pal I, Banik P, Chakraborty S, Borkar S, Dey G Acta Pharmacol Sin. 2017; 38(5):591-613.

PMID: 28317871 PMC: 5457688. DOI: 10.1038/aps.2016.167.

Immunological low-dose radiation modulates the pediatric medulloblastoma antigens and enhances antibody-dependent cellular cytotoxicity.

Das A, McDonald D, Lowe S, Bredlau A, Vanek K, Patel S Childs Nerv Syst. 2016; 33(3):429-436.

PMID: 27942918 DOI: 10.1007/s00381-016-3305-x.

Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells efficiently control the development of human glioblastoma brain tumors.

Jarry U, Chauvin C, Joalland N, Leger A, Minault S, Robard M Oncoimmunology. 2016; 5(6):e1168554.

PMID: 27471644 PMC: 4938356. DOI: 10.1080/2162402X.2016.1168554.

References

Mitsuyasu R, Anton P, Deeks S, Scadden D, Connick E, Downs M . Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood. 2000; 96(3):785-93. View

Han S, Kaur G, Yang I, Lim M . Biologic principles of immunotherapy for malignant gliomas. Neurosurg Clin N Am. 2009; 21(1):1-16. DOI: 10.1016/j.nec.2009.08.001. View

Mavligit G, Gutterman J, Hersh E . Primary brain tumors: tumor immunity and immunocompetence. Surg Neurol. 1973; 1(5):261-3. View

Lamb Jr L . Gammadelta T cells as immune effectors against high-grade gliomas. Immunol Res. 2009; 45(1):85-95. DOI: 10.1007/s12026-009-8114-9. View

Sadelain M, Riviere I, Brentjens R . Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003; 3(1):35-45. DOI: 10.1038/nrc971. View

Kershaw M, Wang G, Westwood J, Pachynski R, Tiffany H, Marincola F . Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther. 2002; 13(16):1971-80. DOI: 10.1089/10430340260355374. View

Peggs K, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss P . Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003; 362(9393):1375-7. DOI: 10.1016/S0140-6736(03)14634-X. View

Hayes R, Koslow M, Hiesiger E, Hymes K, Hochster H, Moore E . Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer. 1995; 76(5):840-52. DOI: 10.1002/1097-0142(19950901)76:5<840::aid-cncr2820760519>3.0.co;2-r. View

Young H, Kaplan A, Regelson W . Immunotherapy with autologous white cell infusions ("lymphocytes") in the treatment of recurrrent glioblastoma multiforme: a preliminary report. Cancer. 1977; 40(3):1037-44. DOI: 10.1002/1097-0142(197709)40:3<1037::aid-cncr2820400311>3.0.co;2-9. View

10.

Barba D, Saris S, Holder C, Rosenberg S, Oldfield E . Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg. 1989; 70(2):175-82. DOI: 10.3171/jns.1989.70.2.0175. View

11.

Stephan M, Ponomarev V, Brentjens R, Chang A, Dobrenkov K, Heller G . T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007; 13(12):1440-9. DOI: 10.1038/nm1676. View

12.

Kahlon K, Brown C, Cooper L, Raubitschek A, Forman S, Jensen M . Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004; 64(24):9160-6. DOI: 10.1158/0008-5472.CAN-04-0454. View

13.

Wu A, Wei J, Kong L, Wang Y, Priebe W, Qiao W . Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010; 12(11):1113-25. PMC: 3098021. DOI: 10.1093/neuonc/noq082. View

14.

Fujita M, Zhu X, Sasaki K, Ueda R, Low K, Pollack I . Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol. 2008; 180(4):2089-98. DOI: 10.4049/jimmunol.180.4.2089. View

15.

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

16.

Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U . NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood. 2007; 111(3):1428-36. DOI: 10.1182/blood-2007-07-101311. View

17.

Friese M, Platten M, Lutz S, Naumann U, Aulwurm S, Bischof F . MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res. 2003; 63(24):8996-9006. View

18.

Pule M, Savoldo B, Myers G, Rossig C, Russell H, Dotti G . Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008; 14(11):1264-70. PMC: 2749734. DOI: 10.1038/nm.1882. View

19.

Milone M, Fish J, Carpenito C, Carroll R, Binder G, Teachey D . Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009; 17(8):1453-64. PMC: 2805264. DOI: 10.1038/mt.2009.83. View

20.

Wei J, Barr J, Kong L, Wang Y, Wu A, Sharma A . Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther. 2010; 9(1):67-78. PMC: 2939737. DOI: 10.1158/1535-7163.MCT-09-0734. View